Xenetic Biosciences, Inc. Employee Directory
Biotechnology ResearchMassachusetts, United States2-10 Employees
Xenetic Biosciences, Inc., based in Framingham, Massachusetts, operates in the biotechnology research sector focusing on cancer therapies. Its XCART program is a personalized CAR T platform designed to target patient-specific tumor neoantigens, with initial work aimed at B-cell lymphomas by focusing on the B-cell receptor on malignant cells. The company also develops PolyXen, a proprietary drug-delivery technology, and holds an exclusive Takeda license in coagulation disorders with royalty potential. Xenetic pursues collaborations to advance its DNase oncology program, including partnerships with The Scripps Research Institute and with Tokyo Medical University. A recent development is the acceptance of an abstract for presentation at the 2026 ASCO Annual Meeting in Chicago.